|Epigenetic differences arise during the lifetime of monozygotic twins|
MF Fraga, E Ballestar, MF Paz, S Ropero, F Setien, ML Ballestar, ...
Proceedings of the National Academy of Sciences 102 (30), 10604-10609, 2005
|Driver mutations in histone H3. 3 and chromatin remodelling genes in paediatric glioblastoma|
J Schwartzentruber, A Korshunov, XY Liu, DTW Jones, E Pfaff, K Jacob, ...
Nature 482 (7384), 226-231, 2012
|Aberrant CpG-island methylation has non-random and tumour-type–specific patterns|
JF Costello, MC Frühwald, DJ Smiraglia, LJ Rush, GP Robertson, X Gao, ...
Nature genetics 24 (2), 132-138, 2000
|Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma|
D Sturm, H Witt, V Hovestadt, DA Khuong-Quang, DTW Jones, ...
Cancer cell 22 (4), 425-437, 2012
JF Costello, C Plass
Journal of medical genetics 38 (5), 285-303, 2001
|Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas|
S Bender, Y Tang, AM Lindroth, V Hovestadt, DTW Jones, M Kool, ...
Cancer cell 24 (5), 660-672, 2013
|Principles for the post-GWAS functional characterization of cancer risk loci|
ML Freedman, ANA Monteiro, SA Gayther, GA Coetzee, A Risch, C Plass, ...
Nature genetics 43 (6), 513-518, 2011
|Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia|
A Raval, SM Tanner, JC Byrd, EB Angerman, JD Perko, SS Chen, ...
Cell 129 (5), 879-890, 2007
|Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia|
W Blum, RB Klisovic, B Hackanson, Z Liu, S Liu, H Devine, ...
Journal of Clinical Oncology 25 (25), 3884-3891, 2007
|Maftools: efficient and comprehensive analysis of somatic variants in cancer|
A Mayakonda, DC Lin, Y Assenov, C Plass, HP Koeffler
Genome research 28 (11), 1747-1756, 2018
|MGMT testing—the challenges for biomarker-based glioma treatment|
W Wick, M Weller, M Van Den Bent, M Sanson, M Weiler, A Von Deimling, ...
Nature Reviews Neurology 10 (7), 372, 2014
|The functional consequences of alternative promoter use in mammalian genomes|
RV Davuluri, Y Suzuki, S Sugano, C Plass, THM Huang
Trends in Genetics 24 (4), 167-177, 2008
|Predicting aberrant CpG island methylation|
FA Feltus, EK Lee, JF Costello, C Plass, PM Vertino
Proceedings of the National Academy of Sciences 100 (21), 12253-12258, 2003
|Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis|
N Cabezas-Wallscheid, D Klimmeck, J Hansson, DB Lipka, A Reyes, ...
Cell stem cell 15 (4), 507-522, 2014
|Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer|
C Plass, SM Pfister, AM Lindroth, O Bogatyrova, R Claus, P Lichter
Nature reviews genetics 14 (11), 765-780, 2013
|Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer|
J Weischenfeldt, R Simon, L Feuerbach, K Schlangen, D Weichenhan, ...
Cancer cell 23 (2), 159-170, 2013
|Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer|
A Krohn, T Diedler, L Burkhardt, PS Mayer, C De Silva, ...
The American journal of pathology 181 (2), 401-412, 2012
|Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21Cip1 promoter|
WG Zhu, K Srinivasan, Z Dai, W Duan, LJ Druhan, H Ding, L Yee, ...
Molecular and cellular biology 23 (12), 4056-4065, 2003
|Genome-wide epigenetic regulation of miRNAs in cancer|
C Baer, R Claus, C Plass
Cancer research 73 (2), 473-477, 2013
|SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers|
H Li, L Myeroff, D Smiraglia, MF Romero, TP Pretlow, L Kasturi, ...
Proceedings of the National Academy of Sciences 100 (14), 8412-8417, 2003